New cocktail of drugs shows promise for tough stomach cancer
NCT ID NCT05702229
First seen Nov 01, 2025
Summary
This Phase 2 trial is testing several new drug combinations in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The study aims to see if these combinations can shrink tumors and keep them from growing for at least 6 months. About 163 participants will receive different combinations of immunotherapy and chemotherapy drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGLos Angeles, California, 90017, United States
-
Research Site
WITHDRAWNLos Angeles, California, 90095, United States
-
Research Site
RECRUITINGBaton Rouge, Louisiana, 70817, United States
-
Research Site
RECRUITINGGrand Rapids, Michigan, 49503, United States
-
Research Site
WITHDRAWNNew Hyde Park, New York, 11042, United States
-
Research Site
WITHDRAWNNew York, New York, 10028, United States
-
Research Site
RECRUITINGNew York, New York, 10065, United States
-
Research Site
WITHDRAWNNew York, New York, 11210, United States
-
Research Site
WITHDRAWNShirley, New York, 11967, United States
-
Research Site
WITHDRAWNThe Bronx, New York, 10469, United States
-
Research Site
WITHDRAWNPittsburgh, Pennsylvania, 15212, United States
-
Research Site
RECRUITINGBeijing, 100142, China
-
Research Site
RECRUITINGHangzhou, 310003, China
-
Research Site
RECRUITINGHangzhou, 310020, China
-
Research Site
RECRUITINGHarbin, 150081, China
-
Research Site
RECRUITINGHefei, 230031, China
-
Research Site
COMPLETEDKunming, 650118, China
-
Research Site
RECRUITINGWuhan, 430079, China
-
Research Site
RECRUITINGYinchuan, 750004, China
-
Research Site
RECRUITINGZhengzhou, 450052, China
-
Research Site
RECRUITINGChūōku, 104-0045, Japan
-
Research Site
RECRUITINGKashiwa, 227-8577, Japan
-
Research Site
RECRUITINGSunto-gun, 411-8777, Japan
-
Research Site
RECRUITINGSeoul, 03080, South Korea
-
Research Site
RECRUITINGSeoul, 03722, South Korea
-
Research Site
RECRUITINGSeoul, 05505, South Korea
-
Research Site
RECRUITINGSeoul, 06351, South Korea
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGElche(Alicante), 03202, Spain
-
Research Site
RECRUITINGL'Hospitalet de Llobregat, 08908, Spain
-
Research Site
RECRUITINGMadrid, 28007, Spain
-
Research Site
RECRUITINGMadrid, 28040, Spain
-
Research Site
RECRUITINGSantander, 39008, Spain
-
Research Site
RECRUITINGHsinchu, 300, Taiwan
-
Research Site
RECRUITINGKaohsiung City, 80756, Taiwan
-
Research Site
RECRUITINGTaichung, 404, Taiwan
-
Research Site
RECRUITINGTainan, 70403, Taiwan
-
Research Site
RECRUITINGTaipei, 10002, Taiwan
-
Research Site
RECRUITINGTaipei, 11259, Taiwan
-
Research Site
RECRUITINGTaoyuan, 333, Taiwan
-
Research Site
WITHDRAWNEdinburgh, EH4 2XU, United Kingdom
-
Research Site
RECRUITINGLeeds, LS9 7TF, United Kingdom
-
Research Site
RECRUITINGLondon, EC1M 6BQ, United Kingdom
-
Research Site
RECRUITINGOxford, OX3 7LE, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rilvegostomig, Volrustomig, FOLFOX, XELOX, AZD0901, 5-Fluorouracil, Capecitabine
What this could lead to
If successful, this could point toward more effective combination treatments for advanced gastric cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early Phase 2 trial with a small number of participants, so results may not apply to all patients. The drug combinations may cause significant side effects or fail to show benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.